> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Generic Drugs Office Modifies Scientific Priorities
- URL: https://www.fdaweb.com/fda-generic-drugs-office-modifies-scientific-priorities/
- Published: 2021-09-24T12:00:00.000Z
- Updated: 2026-09-14T17:16:03.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150218

The CDER Office of Generic Drugs (OGD) has revised its [scientific priorities](https://www.fda.gov/media/144140/download?ref=fdaweb.com) as part of its user fee performance goals through 2022\. For example, a research priority initiative to develop better methods for evaluating opioid product abuse deterrence that was included in the FY 2020 priorities was removed from the current priorities because FDA’s ongoing research in this area is sufficient to address the identified needs. “The success of our research programs on alternative bioequivalence (BE) methods for topical and ophthalmic products has led to the completion of these priorities and a new focus on expanding alternative BE methods to a larger space of formulation differences,” OGD says.

Regarding inhalation drug products, previous research has allowed OGD to change the focus from development of new BE approaches to implementation of new approaches. “Research priorities to optimize BE study design and methodologies to evaluate modified study designs have been proposed for FY 2021 as a response to the ongoing Covid-19 pandemic,” OGD says. “A new focus of our modeling and simulation research for oral products will support ongoing global harmonization of BE standards via the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) process.”